U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H28N2O4
Molecular Weight 348.4366
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROXATIDINE ACETATE

SMILES

CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1

InChI

InChIKey=SMTZFNFIKUPEJC-UHFFFAOYSA-N
InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)

HIDE SMILES / InChI

Molecular Formula C19H28N2O4
Molecular Weight 348.4366
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.drugsupdate.com/generic/view/456/Roxatidine | https://www.ncbi.nlm.nih.gov/pubmed/1717223 | https://www.ncbi.nlm.nih.gov/pubmed/20718616

Roxatidine is an histamine H2-receptor antagonist. Roxatidine is a potent and selective inhibitor of basal and stimulated gastric acid secretion through competitive blockade of H2-receptors. Total pepsin secretion is reduced in a dose-dependent manner. There is an independent mucosal protection action. Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome also it can be used as a premedication before anaesthesia. Roxatidine possessed a robust estrogenic activity.

CNS Activity

Curator's Comment: Small amounts of roxatidine were detectable in the CSF, the CSF to plasma ratio ranging from 0 to 0.89.

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Peptic ulcer: 150 mg at bedtime or 75 mg bid daily for 4-6 weeks. Maintenance: 75 mg at bedtime. Gastro-oesophageal reflux disease: 75 mg bid or 150 mg at bedtime for 6-8 weeks. Gastritis: 75 mg once daily in the evening. Zollinger-Ellison syndrome: 75 mg bid. Premedication before anaesthesia: 75 mg in the evening on the day before surgery and repeated 2 hours before induction of anaesthesia. Alternatively, 150 mg once on the night before surgery. Intravenous Upper gastrointestinal haemorrhage: 75 mg bid via slow injection or infusion.
Route of Administration: Other
6.25-25 uM Roxatidine suppressed the PMACI-induced production of pro-inflammatory cytokines in HMC-1
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:01:01 UTC 2023
Edited
by admin
on Fri Dec 15 19:01:01 UTC 2023
Record UNII
ZUP3LSD0DO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROXATIDINE ACETATE
MI   VANDF   WHO-DD  
Common Name English
ACETAMIDE, 2-(ACETYLOXY)-N-(3-(3-(1-PIPERIDINYLMETHYL)PHENOXY)PROPYL-
Common Name English
Roxatidine acetate [WHO-DD]
Common Name English
ROXATIDINE ACETATE [VANDF]
Common Name English
PIFATIDINE
Common Name English
ROXATIDINE ACETATE [MI]
Common Name English
Code System Code Type Description
RXCUI
35803
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY RxNorm
EVMPD
SUB04277MIG
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY
EPA CompTox
DTXSID2048325
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY
CAS
78628-28-1
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY
MERCK INDEX
m9677
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY Merck Index
PUBCHEM
5105
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY
SMS_ID
100000084943
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY
DRUG CENTRAL
2408
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY
FDA UNII
ZUP3LSD0DO
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY
ChEMBL
CHEMBL46102
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY
MESH
C053742
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY
DRUG BANK
DB08806
Created by admin on Fri Dec 15 19:01:01 UTC 2023 , Edited by admin on Fri Dec 15 19:01:01 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY